How to access Aptiom for partial-onset (focal) epilepsy from Oman: 2026 pathway via Oman neurology and community pharmacy supply
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Oman has a focused adult and paediatric neurology service footprint. Royal Hospital Muscat neurology, Sultan Qaboos University Hospital (SQUH) neurology, Oman Defence Force Hospital neurology, Muscat Private Hospital, and private neurology clinics across Manama and Riffa all treat partial-onset (focal) epilepsy from the initial diagnostic workup through long-term medication management. For complex medication-refractory cases requiring video-EEG monitoring or epilepsy surgery evaluation, cross-border referral to KFSHRC Riyadh or HMC Doha is the established pattern. Aptiom (eslicarbazepine acetate; the international Zebinix brand is the same molecule from Bial) is the third-generation sodium-channel inhibitor in the dibenzazepine family, once-daily, with a cleaner enzyme-induction and hyponatraemia profile than carbamazepine or oxcarbazepine. For a Oman-resident adult or paediatric patient aged 4 or over with confirmed partial-onset seizures, the operational question is which prescribing centre fits the case, whether the prescription can be dispensed in-country or requires a named-patient cross-border supply pathway, and how insurance and out-of-pocket exposure work for the multi-year treatment course. The DGPADC (Directorate General of Pharmaceutical Affairs and Drug Control) registration pathway governs the in-country drug-availability picture.
This page explains how the pathway works in 2026 for a Oman-resident patient: who qualifies, where the neurologist conversation happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in OMR, what to monitor on therapy, and how the longer-term treatment course fits into an Omani family's life.
Why Aptiom, and why now
Aptiom is eslicarbazepine acetate, a once-daily oral voltage-gated sodium channel blocker, prodrug to eslicarbazepine, the active S-enantiomer of the carbamazepine 10-monohydroxy metabolite. Developed by Bial (Portugal), commercialised internationally as Zebinix, licensed to Sunovion as Aptiom for the US market.
FDA: adult adjunctive November 2013, adult monotherapy September 2015, paediatric ages 4 and over September 2017. EMA approved Zebinix in April 2009.
For an Omani patient who has trialled levetiracetam or lamotrigine without adequate seizure control, or who is moving off carbamazepine because of hyponatraemia or unfavourable interactions, Aptiom is the operational answer: once-daily, cleaner enzyme-induction profile, lower hyponatraemia incidence than oxcarbazepine.
What Aptiom is, in plain language
Oral tablet, once daily, with or without food. 200 mg, 400 mg, 600 mg, 800 mg strengths. Crushable. Room temperature storage. No infusion, no certified-centre requirement.
Adult titration: 400 mg week 1, 800 mg week 2 onwards, maintenance 800 to 1,600 mg/day. Paediatric (ages 4 to 17): weight-based, 20 to 30 mg/kg/day maintenance.
Eligibility at a Oman neurology clinic
1. Confirmed partial-onset (focal) epilepsy diagnosed by neurologist or epileptologist with EEG and MRI brain documentation. 2. Age 4 or older for paediatric prescribing. 3. Treatment history demonstrating failure of an initial first-line antiepileptic or tolerability-driven need to move off carbamazepine or oxcarbazepine. 4. Baseline serum sodium and liver function tests. 5. Hormonal contraceptive review for women of reproductive potential. 6. Pregnancy and lactation screen. 7. Drug interaction screen. 8. Hepatic and renal function review. 9. HLA screening where clinically indicated.
An Omani patient should arrive with EEG report, MRI brain report, complete seizure history, prior antiepileptic-drug history, baseline labs, and insurance documentation.
Oman prescribing and dispense picture, plainly
Zebinix availability in Oman depends on DGPADC registration status at the point of prescription. [VERIFY: current DGPADC Zebinix registration status at point of dispense.] Where Zebinix is registered and commercially supplied through Bial's regional distributor network, in-country dispensing applies. Where the indication or formulation extension has not yet been registered locally, a named-patient pathway can apply for documented physician-initiated prescriptions referencing an FDA, EMA, or MHRA approved indication, with cross-border procurement from Saudi or UAE distributors.
1. Prescribing neurologist or epileptologist: any board-certified Omani neurologist. Major Omani neurology services include Royal Hospital Muscat (the kingdom's flagship MoH tertiary hospital), Sultan Qaboos University Hospital (SQUH) (with adult and paediatric neurology), Oman Defence Force Hospital neurology, Muscat Private Hospital, the Aster network, and private neurology clinics across Manama and Riffa. For complex medication-refractory cases, cross-border referral to KFSHRC Riyadh or HMC Doha for video-EEG monitoring or epilepsy surgery evaluation is the established pattern. 2. Diagnostic workup: EEG and MRI brain run at Royal Hospital Muscat, King Hamad, BDF Hospital, or partnered private-sector neurology service. Standard EEG is widely available; video-EEG monitoring is more limited in-country and complex cases are referred to KFSHRC Riyadh or HMC Doha. 3. Insurance pre-authorisation: for Omani nationals, MoH cover for AEDs at the maintenance dose tier is generally available with documented neurologist prescription. Commercial cover (AXA Gulf, Oman National Insurance, GIG Oman, the regional Bupa product) varies; some require a clinical rationale letter documenting prior AED failure or intolerance. 4. Pharmacy dispense: hospital pharmacy for inpatient or specialty outpatient settings; community pharmacy for ongoing maintenance. For named-patient supply, cross-border procurement from KSA or UAE distributors may apply, with modest overhead for documentation and logistics. 5. Refill cycle: monthly. Continued dispensing requires documentation of ongoing seizure-diary review and periodic serum sodium monitoring.
The 2026 pathway, step by step
Week 0 to 2: Documentation pack with treating neurologist's office, including DGPADC registration status check at point of prescription.
Week 2 to 4: Insurance pre-authorisation review.
Week 4 to 5: First dispense (in-country if registered, or via named-patient cross-border supply). Starting dose 400 mg once daily for one week.
Week 5 to 6: Up-titration to 800 mg once daily.
Week 4 and month 3: Serum sodium checks.
Ongoing: Maintenance once daily, monthly refill, annual serum sodium check, periodic LFT monitoring, continuous seizure diary.
Cost expectation in OMR
US Aptiom list price (2026) approximately USD 1,200 to USD 2,000 per 30-day supply; annual cost USD 14,000 to USD 24,000 at list price. International Zebinix supply generally lower.
At 2026 cross rates, a 30-day Aptiom supply at USD 1,500 is approximately OMR 565, annual cost at USD 18,000 is approximately OMR 6,780. Zebinix supply through Oman channel typically lands in the OMR 380 to 565 monthly band, with annual cost in the OMR 4,200 to 6,780 band.
For Omani nationals, MoH cover for AEDs at the maintenance dose tier is generally available. Commercial cover varies. Cross-border named-patient supply adds modest overhead.
Monitoring on therapy
- Serum sodium: baseline, one month, three months, then annually if stable. - Liver function tests: baseline and periodically. - Seizure diary: contin